AR and prostate carcinoma: In contrast, although JMJD2D can associate with and thereby modulate DNA-binding transcription factors involved in prostate cancer, namely the androgen receptor and the ETS proteins ETV1 and ETV2 (18–20), no evidence has been presented that JMJD2D could stimulate prostate cancer cells or affect prostate tumor formation.